Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Topigen and Novagali collaborate on allergic ocular diseases and allergic rhinitis
April 2007
SHARING OPTIONS:

MONTREAL—Topigen Pharmaceuticals Inc., a biopharmaceutical company specializing in respiratory disorders, and Novagali Pharma S.A., an Evry, France-based specialty biopharma developing novel ophthalmic products, announced in late March a strategic collaboration and cross-license agreement. Financial terms of the deal were not disclosed.
 
Under the terms of the agreement, Novagali will receive an exclusive worldwide license to develop and commercialize an ophthalmic product based on Topigen's multi-targeted, RNA-targeting platform technology for the treatment and prevention of allergic eye diseases. Topigen will receive an exclusive license to Novagali's Novasorb topical delivery technology for use in formulating and developing an RNA-targeted therapy for treating respiratory conditions like allergic rhinitis.
 
Topigen and Novagali will collaborate to develop ocular and nasal forms of RNA-targeting product candidates based on Novagali's Novasorb technology and work to improve the bioadhesion and hence the efficacy of RNA-targeting therapeutics.
 
The agreement enables Novagali to develop its own ophthalmic product based on Topigen's RNA-targeting platform technology for allergic eye diseases, and for Topigen to develop its own RNA-targeting products for allergic rhinitis based on the formulations developed using the Novasorb technology.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.